Founded in 2001, the Queen's Cancer Research Institute (QCRI) has grown into the largest research concentration in the Faculty of Health Sciences.
Research at the 60,000-square foot facility ranges from population studies of cancer etiology, through tumour biology and clinical trials, to outcomes, and health services research. The QCRI is committed to improving cancer control through research that spans disciplines and investigates connections among fundamental, clinical, and population research.
The QCRI is home to three divisions that conduct cancer research at different scales, ranging from single molecules to populations in Canada and across the globe:
The Cancer Biology and Genetics Division carries out molecular, cellular, genomic, and translational studies in cancer diagnostics, mechanisms of tumour progression, and in drug development, metabolism, and resistance.
The Cancer Care and Epidemiology Division (CCE) investigates the etiology of cancer as well as strategies to improve access to high-quality care for patients in Canada and beyond.
The Canadian Cancer Trials Group (CCTG), the country’s premier cooperative oncology group, carries out investigator-initiated clinical trials featuring a diverse portfolio of therapeutic, supportive care, and prevention strategies in all age groups and all cancer types. The CCTG has two main areas of study: investigational new drugs and comparative randomized trials.